Vortioxetine Hydrobromide Particle Size Distribution for Bioequivalence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing pharmaceutical compositions of vortioxetine hydrobromide face challenges due to its poor solubility and vulnerability to polymorphic changes, limiting the use of larger crystal sizes, and prior art lacks stable and reproducible bioequivalent formulations with novel particle size distributions.
Innovation Solution
A stable, reproducible, and bioequivalent pharmaceutical composition is developed using vortioxetine hydrobromide with a particle size distribution of D98 100-200μ, D50 35-90μ, and D5 7-30μ, produced through spray granulation or wet granulation, which deviates from traditional methods and particle sizes, ensuring bioequivalence and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If larger crystal sizes of vortioxetine hydrobromide are used, then manufacturing ease is improved, but solubility and bioavailability deteriorate
Solution Approach 1:
The patent segments the crystal size distribution into specific ranges (D98: 650-680 μm, D50: 230-250 μm, D5: 40-60 μm) to balance manufacturing ease with solubility requirements. This segmentation allows larger crystals for ease of handling while maintaining a distribution that ensures adequate dissolution rate and bioavailability.
2Ease of manufacture
If vortioxetine hydrobromide is subjected to polymorphic changes, then crystal structure stability deteriorates, but formulation development becomes more difficult
Solution Approach 1:
The patent specifies precise particle size distribution parameters (D98, D50, D5 values) as critical quality attributes to control polymorphic stability. By establishing these specific parameter ranges, the formulation ensures reproducible crystal structure and prevents unwanted polymorphic transformations during manufacturing and storage.
3Ease of manufacture
If particle size distribution is not optimized, then manufacturing simplicity is improved, but dissolution rate and bioavailability deteriorate
Solution Approach 1:
The patent establishes a dynamic particle size distribution profile rather than a single fixed size. The distribution allows flexibility in manufacturing while ensuring that the majority of particles fall within optimal dissolution ranges, balancing manufacturing simplicity with pharmacokinetic performance.
Data Source
AI summary
The invention relates to vortioxetine hydrobromide having particle size distribution of D98 100-200μ, D50 35-90μ and D5 7-30μ as well as to a stable, reproducible and bioequivalent pharmaceutical composition comprising vortioxetine hydrobromide having particle size distribution of D98 100-200μ, D50 35-90μ and D5 7-30μ and one or more pharmaceutically acceptable excipient. It is produced by wet granulation techniques.